STATERA BIOPHARMA INC (STAB) Stock Price, Forecast & Analysis
USA - NASDAQ:STAB - US8575611046 - Common Stock
STAB Key Statistics, Chart & Performance
The current stock price of STAB is 0.0911 USD. In the past month the price decreased by -20.09%. In the past year, price decreased by -95.38%.
STAB Latest News, Press Relases and Analysis
STAB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.58 | 410.35B | ||
| AMGN | AMGEN INC | 15.36 | 180.89B | ||
| GILD | GILEAD SCIENCES INC | 15.29 | 155.35B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.03 | 111.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.44 | 73.66B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 890.14 | 59.51B | ||
| INSM | INSMED INC | N/A | 40.36B | ||
| NTRA | NATERA INC | N/A | 27.54B | ||
| BIIB | BIOGEN INC | 9.84 | 24.15B | ||
| INCY | INCYTE CORP | 16.42 | 20.58B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.52 | 20.91B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.49 | 14.30B |
Related stock screener links
About STAB
Company Profile
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is headquartered in Fort Collins, Colorado and currently employs 46 full-time employees. The company went IPO on 2006-07-21. The firm is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers. Its Advanced Immunomodulating Multi-Component System (AIMS) platform is designed to rebalance the body's immune system and restore homeostasis. Its platforms of toll-like receptor (TLR) agonists include R4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. Through its AIMS platform, the Company develops product candidates, which include STAT-200 and STAT-600 AIMS programs. Its STAT-200 program include STAT-201 is focused on treatment of Crohn’s disease. The firm has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205).
Company Info
STATERA BIOPHARMA INC
2537 Research Boulevard, Suite 201
Fort Collins COLORADO US
CEO: Christopher Zosh
Employees: 46
Phone: 18886138802.0
STATERA BIOPHARMA INC / STAB FAQ
What does STAB do?
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is headquartered in Fort Collins, Colorado and currently employs 46 full-time employees. The company went IPO on 2006-07-21. The firm is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers. Its Advanced Immunomodulating Multi-Component System (AIMS) platform is designed to rebalance the body's immune system and restore homeostasis. Its platforms of toll-like receptor (TLR) agonists include R4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. Through its AIMS platform, the Company develops product candidates, which include STAT-200 and STAT-600 AIMS programs. Its STAT-200 program include STAT-201 is focused on treatment of Crohn’s disease. The firm has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205).
Can you provide the latest stock price for STATERA BIOPHARMA INC?
The current stock price of STAB is 0.0911 USD. The price decreased by -5.2% in the last trading session.
Does STATERA BIOPHARMA INC pay dividends?
STAB does not pay a dividend.
What is the ChartMill rating of STATERA BIOPHARMA INC stock?
STAB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Should I buy STAB stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on STAB.
What is the next earnings date for STAB stock?
STATERA BIOPHARMA INC (STAB) will report earnings on 2023-03-29.
What is the outstanding short interest for STATERA BIOPHARMA INC?
The outstanding short interest for STATERA BIOPHARMA INC (STAB) is 0.17% of its float.
STAB Technical Analysis
STAB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to STAB. STAB may be in some trouble as it scores bad on both profitability and health.
STAB Financial Highlights
Over the last trailing twelve months STAB reported a non-GAAP Earnings per Share(EPS) of -1.72. The EPS decreased by -71.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |